IN2013MU03370A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03370A
IN2013MU03370A IN3370MU2013A IN2013MU03370A IN 2013MU03370 A IN2013MU03370 A IN 2013MU03370A IN 3370MU2013 A IN3370MU2013 A IN 3370MU2013A IN 2013MU03370 A IN2013MU03370 A IN 2013MU03370A
Authority
IN
India
Prior art keywords
self
delivery system
drug delivery
emulsifying drug
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN3370MU2013 priority Critical patent/IN2013MU03370A/en
Priority to PCT/GB2014/053142 priority patent/WO2015059466A1/en
Publication of IN2013MU03370A publication Critical patent/IN2013MU03370A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3370MU2013 2013-10-25 2014-10-22 IN2013MU03370A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3370MU2013 IN2013MU03370A (es) 2013-10-25 2014-10-22
PCT/GB2014/053142 WO2015059466A1 (en) 2013-10-25 2014-10-22 Pharmaceutical compositions comprising efavirenz

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3370MU2013 IN2013MU03370A (es) 2013-10-25 2014-10-22

Publications (1)

Publication Number Publication Date
IN2013MU03370A true IN2013MU03370A (es) 2015-09-25

Family

ID=51947382

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3370MU2013 IN2013MU03370A (es) 2013-10-25 2014-10-22

Country Status (2)

Country Link
IN (1) IN2013MU03370A (es)
WO (1) WO2015059466A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019003150A2 (en) 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS
ES2732498B2 (es) * 2018-05-21 2020-04-27 Consejo Superior Investigacion Uso de efavirenz para el tratamiento de enfermedades de almacenamiento lipidico.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv

Also Published As

Publication number Publication date
WO2015059466A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
EP3272387A4 (en) Drug administration device, and manufacturing method for drug administration device
EP3445416A4 (en) ENTERALES ACTIVE COMPOSITION SYSTEM
EP3313499A4 (en) DEVICES, SYSTEMS AND METHODS FOR INCREASING THE INTRALUMINAL DRUG DELIVERY AND RECEIVING
PH12019501076A1 (en) Pharmaceutical formulations
PH12016501841A1 (en) Immunosuppressant formulation
MX2017016802A (es) Formulaciones farmaceuticas.
EP3664885A4 (en) TRANSDERMAL DRUG DELIVERY SYSTEM
EP3710079A4 (en) SYSTEMS, DEVICES, FORMULATIONS AND PROCEDURES FOR CONTROLLED INGREDIENT DELIVERY
IL273704A (en) Pharmaceutical bilayer tablet formulations
EP3801703A4 (en) IN-FABRIC DRUG DELIVERY SYSTEM
EP3373977A4 (en) CELLULAR PENETRATION-RICH GUANIDINIC OLIGOPHOSPHOTRIESTERS FOR THE DELIVERY OF MEDICATION AND PROBE
IN2013MU01985A (es)
EP3534987A4 (en) ADJUSTABLE-DOSE DRUG DELIVERY SYSTEM
EP3288544A4 (en) Hypromellose-graft-chitosan and methods thereof for sustained drug delivery
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
EP4049698A4 (en) DRUG DELIVERY DEVICE
IN2013MU03370A (es)
IL275664A (en) drug delivery system
EP3925647A4 (en) DRUG SOLUTION DELIVERY DEVICE
IN2014MU00043A (es)
WO2019059868A3 (en) PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ
EP3760249A4 (en) DRUG SOLUTION ADMINISTRATION DEVICE
EP3733243A4 (en) DRUG ADMINISTRATION PROCEDURE